JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 內幕消息 2025 年第三季度之未經審計最新資料 本公告乃由京东健康股份有限公司（「本公司」或「京東健康」，連同其子公司及關聯併表 實體統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義 見上市規則）而刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 業務最新資料 2025年第三季度，京東健康與禮來、信達生物、衛材中國及拜耳中國等知名藥企簽署戰 略合作協定。衛材藥企旗下原研新藥達衛可® （萊博雷生片）、恒瑞旗下乾眼症新藥恆沁® （全氟己基辛烷滴眼液）、拜耳旗下達喜® 乳果糖等新藥也選擇在京東健康全網首發，繼 續鞏固京東健康「新特藥全網首發第一站」心智。除藥 ...

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has signed a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, offering a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing a unique product pipeline and expertise in patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health (09955) and JD Health (06618) aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health, as the largest pharmaceutical e-commerce platform in China, offers a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Market Implications - The collaboration is expected to leverage the unique product pipeline and patient management expertise of Zhiyun Health, enhancing the overall service offering [1] - This strategic move aligns with the growing trend of digital health solutions and e-commerce in the pharmaceutical industry [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Lifemin tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, boasting a vast user base and extensive platform resources [1] - The partnership signifies a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing unique product pipelines and professional capabilities in doctor-patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand online sales and service channels for Livermore tablets and other P2M pipeline products, aiming to provide patients with a more convenient purchasing experience and professional full-cycle health management services [1] Group 1 - The partnership with JD Health is intended to enhance the accessibility of Zhiyun Health's products [1] - The agreement focuses on improving the online sales channels for Livermore tablets and other products in the P2M pipeline [1] - The initiative aims to offer patients a more convenient way to purchase medications and access health management services [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between a leading chronic disease management platform and a prominent e-commerce platform, enhancing the overall service offering to patients [1] - The initiative is positioned to improve patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Lifemin tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, boasting a vast user base and extensive platform resources [1] - The partnership signifies a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - The collaboration is expected to leverage Zhiyun Health's unique product pipeline and expertise in chronic disease management [1] - The initiative aims to provide professional full-cycle health management services to patients [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Company Strengths - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, indicating its significant market presence [1] - Zhiyun Health is noted for its leadership in chronic disease management, possessing a unique product pipeline and expertise in patient management [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between two leading companies in their respective fields, enhancing the potential for effective promotion of health management solutions [1] - The partnership will facilitate better patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]

Group 1 - The core viewpoint of the article emphasizes the establishment of a comprehensive health management platform by JD Health, focusing on pharmaceutical e-commerce and medical services to cover the entire user lifecycle [1][2] - JD Health, founded in 2018, has become the largest pharmaceutical health retail channel in China, leveraging the advantages of the parent company's traffic, supply chain capabilities, and logistics system [1] - The opening of online medical insurance purchasing rights is identified as a significant short-term catalyst for the industry, with various regions expected to gradually open online medical insurance settlement rights to mainstream online drug purchasing platforms by 2024 [1] Group 2 - The company is strengthening its "self-operated + platform + instant retail" multi-channel collaboration, enhancing brand recognition through self-operated businesses and meeting urgent medication needs through instant retail [2] - By the first half of 2025, the company's online medical insurance payment services are projected to cover nearly 200 million people, which will effectively promote user conversion to online drug purchases [2] - The company is expected to benefit from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment rights, with projected revenues of 70.9 billion, 82.4 billion, and 94.2 billion yuan for 2025-2027, and adjusted net profits of 5.7 billion, 6.2 billion, and 7.2 billion yuan respectively [2]